🟢 Sunshine Biopharma is trading 8.18% up in pre-market with no clear company-specific catalyst identified

Sunshine Biopharma is trading at $3.02, up 8.18% in pre-market, with no clear company-specific catalyst identified.

• The latest company press release located was dated October 22; the reported Q3 earnings date is later in November.
• A November 5 market update also reported a gain without identifying a clear company-specific catalyst. Supplied price context shows a 5.28% gain to $2.79 that day.
• Market context on November 6 is mixed, and available evidence does not establish broader-market sentiment as the reason for the rise.